R&D tax credit included in $700 billion bailout plan
This article was originally published in The Gray Sheet
Extension of research and development tax provisions favored by the device industry is attached to the $700 billion Emergency Economic Stabilization Act of 2008, passed by the House and Senate last week and signed by President Bush Oct. 3 ("1The Gray Sheet" Dec. 10, 2007, p. 14)
You may also be interested in...
Device lobbyists are joining a year-end push for an extension of a soon-to-expire tax credit for companies engaged in research and development, but opportunities are running out
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.